The Absolute Effect / Evidence index
Adjuvant / Postoperative · Phase III randomized; 166 enrolled, 153 centrally ALK-positive resected NSCLC. Crizotinib 250 mg BID up to 2 years vs observation. Primary endpoint DFS. · Median DFS 74.6 vs 75.1 months
ECOG-ACRIN E4512 / ALCHEMIST-ALK
Clinical question: Does adjuvant crizotinib improve DFS over observation after resection of ALK-positive NSCLC?
Median DFS 74.6 vs 75.1 months; HR 1.08 (95% CI 0.61–1.90; P=0.80). Adjuvant crizotinib did not prolong DFS. · Registry:
Design, population and treatment
Phase III randomized; 166 enrolled, 153 centrally ALK-positive resected NSCLC. Crizotinib 250 mg BID up to 2 years vs observation. Primary endpoint DFS.
Key efficacy outcome
Grade ≥3 AEs of any attribution in 58% receiving crizotinib; common diarrhoea, oedema, hypertension.
Safety and absolute effect
Median DFS (months)
https://pmc.ncbi.nlm.nih.gov/articles/PMC13637573/
Interpretation and limitations
Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.